The strategic role of blockchain-enabled federated learning, AI agents and dynamic capabilities in driving pharmaceutical operational advantages

This paper explores the strategic integration of artificial intelligence, blockchain technology and dynamic capabilities (DC) in the pharmaceutical sector. The research utilises a mixed-methods approach that integrates quantitative benchmarking and case studies of six organisations to elucidate the operational realities of technology adoption. The primary findings suggest that a substantial financial investment does not necessarily result in a positive return on investment. Instead, the analysis identifies distinct strategic archetypes, ranging from ‘foundation builders’, characterised by the presence of substantial yet underutilised infrastructure, to ‘lean innovators’, who demonstrate high efficiency with minimal expenditure. A central conclusion of this paper is that DC is the critical enabler that allows companies to translate technological potential into tangible value. Pharmaceutical organisations with robust DCs exhibit considerably higher project success rates and more adeptly leverage their skilled workforce to enhance operational efficiency. The paper provides a data-driven framework for benchmarking these strategic approaches, demonstrating that competitive advantage hinges on aligning technological investments with robust organisational capabilities. This article is also included in The Business & Management Collection which can be accessed at https://hstalks.com/business/.